Clinical utility of the DENOVA score for predicting infective endocarditis in Enterococcus faecalis bacteremia: external validation with decision curve analysis.
The DENOVA score was developed to support risk stratification for infective endocarditis (IE) in patients with Enterococcus faecalis bacteremia (EfB) and to guide echocardiographic evaluation; external validation remains, however, limited. The objective of this study was to externally validate the DENOVA score in a large prospective international cohort of patients with EfB.
Prospective multicenter cohort study (2019-2024) conducted across 23 centers in six countries (Italy, Spain, Israel, Brazil, Switzerland, and Romania), including adult patients with monomicrobial EfB who underwent at least one echocardiographic evaluation as part of the study protocol. Definite IE was defined according to the 2023 Duke criteria. The DENOVA score was externally validated; discrimination was assessed by the area under the receiver operating characteristic curve (AUC), calibration by observed versus predicted risk plots, and clinical utility by decision curve analysis (DCA) at the predefined threshold (DENOVA ≥3). Performance of the NOVA score was evaluated as a secondary analysis.
Among 543 patients, 125/543 (23.0%) were diagnosed with IE. When evaluated as a continuous variable, the DENOVA score showed an AUC of 0.871 (95%CI 0.835-0.906). At the predefined threshold (DENOVA ≥3), sensitivity was 79.2% (95%CI 71.0-85.9) and specificity was 83.0% (95% CI 79.1-86.5). Decision curve analysis showed that DENOVA ≥3 was associated with positive net clinical benefit across most threshold probabilities, with a reduction in unnecessary TEEs.
The study demonstrated that DENOVA supports risk stratification for IE in patients with EfB, informing clinical decision-making and use of TEE.
Prospective multicenter cohort study (2019-2024) conducted across 23 centers in six countries (Italy, Spain, Israel, Brazil, Switzerland, and Romania), including adult patients with monomicrobial EfB who underwent at least one echocardiographic evaluation as part of the study protocol. Definite IE was defined according to the 2023 Duke criteria. The DENOVA score was externally validated; discrimination was assessed by the area under the receiver operating characteristic curve (AUC), calibration by observed versus predicted risk plots, and clinical utility by decision curve analysis (DCA) at the predefined threshold (DENOVA ≥3). Performance of the NOVA score was evaluated as a secondary analysis.
Among 543 patients, 125/543 (23.0%) were diagnosed with IE. When evaluated as a continuous variable, the DENOVA score showed an AUC of 0.871 (95%CI 0.835-0.906). At the predefined threshold (DENOVA ≥3), sensitivity was 79.2% (95%CI 71.0-85.9) and specificity was 83.0% (95% CI 79.1-86.5). Decision curve analysis showed that DENOVA ≥3 was associated with positive net clinical benefit across most threshold probabilities, with a reduction in unnecessary TEEs.
The study demonstrated that DENOVA supports risk stratification for IE in patients with EfB, informing clinical decision-making and use of TEE.
Authors
Varisco Varisco, Piovani Piovani, Del Turco Del Turco, Bussini Bussini, Paul Paul, Sabik Sabik, Castagna Castagna, Ripa Ripa, Gomes Gomes, Di Bella Di Bella, Zerbato Zerbato, Lopez Lopez, Franceschini Franceschini, Bandera Bandera, Oliva Oliva, Gavaruzzi Gavaruzzi, Muñoz Muñoz, Mularoni Mularoni, Seminari Seminari, Morelli Morelli, Pocaterra Pocaterra, Tascini Tascini, Papadimitriou-Olivgeris Papadimitriou-Olivgeris, Coppola Coppola, Cristini Cristini, Russo Russo, Bassetti Bassetti, Travi Travi, Lopez-Contreras Lopez-Contreras, Viale Viale, Cento Cento, Diella Diella, Bavaro Bavaro, Gaibani Gaibani, Giannella Giannella, Bartoletti Bartoletti, , ,
View on Pubmed